Ribupatide Trial Shows Nearly 18% Average Weight Loss
A study published on November 15, 2026, found that an experimental weekly injection called ribupatide helped adults with overweight or obesity lose weight over 48 weeks. The trial, conducted by researchers at Fudan University in Shanghai, enrolled 567 people with an average age of 34.
Participants were assigned to receive a weekly dose of 2, 4 or 6 milligrams, or a placebo. Average weight loss was 10.7% with the lowest dose, 16.4% with 4 milligrams and 17.7% with 6 milligrams. The placebo group lost 1.4%. At least one-fifth of starting body weight was lost by 44.4% of those on the highest dose. Weight loss had not clearly levelled off in the two higher-dose groups by the end of the trial.
The researchers also found improvements in blood pressure, blood sugar measures and cholesterol. Waist measurements fell by an average of 9 to 14 centimetres among participants receiving ribupatide, compared with 2.5 centimetres in the placebo group. Digestive problems, including nausea, vomiting and diarrhoea, were common, particularly at higher doses, but were generally mild or moderate.
The researchers cautioned that the 48-week period may not show the full effect and that the participants’ relatively young age limits how readily the results apply to older adults. UK trials are recruiting to compare ribupatide with a placebo over 18 months, and a separate trial is comparing it directly with semaglutide.
Reported by Daily Mail US, New York Post.







